-

Travere Therapeutics to Report Second Quarter 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

Travere Therapeutics to report second quarter 2025 financial results on August 6, 2025, after the close of the U.S. financial markets.

Share

The webcast and dial-in information can be accessed on the Investor page of Travere’s website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company’s website.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Contacts

Media:
888-969-7879
mediarelations@travere.com

Investors:
888-969-7879
IR@travere.com

Travere Therapeutics, Inc.

NASDAQ:TVTX
Details
Headquarters: San Diego, CA
CEO: Eric Dube, Ph.D.
Employees: 385
Organization: PUB

Release Versions

Contacts

Media:
888-969-7879
mediarelations@travere.com

Investors:
888-969-7879
IR@travere.com

Social Media Profiles
More News From Travere Therapeutics, Inc.

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,088, titled “Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders,” directed to certain methods of using FILSPARI® (sparsentan) in IgA nephropathy. Upon issuance, the patent is expected to provide U.S. patent coverage for certain methods of using sparsentan...

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,800 shares of its common stock to four new employees, consisting of inducement stock options to purchase an aggregate of 18,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 30,800 shares of its common stock. These inducement s...

Travere Therapeutics to Participate at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2026 Health Care Conference Presenting on Wednesday, May 13, 2026, at 5:20 p.m. ET (2:20 p.m. PT) 2026 Jefferies Global Healthcare Conference Presenting on Wednesday, June 3, 2026, at 8:45 a.m. ET Goldman Sachs 47th Annual Global Healthcare Conference 2026 Presenting on Monday, June 8, 2026, at 11:20 a.m. E...
Back to Newsroom